U.S. markets close in 1 hour 20 minutes

CinCor Pharma, Inc. (CINC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
28.86-0.04 (-0.14%)
As of 02:39PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close28.90
Bid28.88 x 800
Ask28.90 x 800
Day's Range28.84 - 29.06
52 Week Range10.53 - 43.15
Avg. Volume607,026
Market Cap1.263B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.40
Earnings DateNov 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CINC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CinCor Pharma, Inc.
    Daily – Vickers Top Buyers & Sellers for 12/27/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • American City Business Journals

    CinCor CEO: acquisition by AstraZeneca was more than a year in the making

    Before CinCor Pharma Inc. agreed to a $1.8 billion acquisition by AstraZeneca plc, it turned down several other offers from the U.K. pharmaceutical giant.

  • Motley Fool

    Why These Two Biotech Stocks Blasted Higher This Week

    Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence.

  • Zacks

    Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More

    Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.